U.S. markets closed

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.0500+0.0400 (+1.33%)
At close: 04:00PM EDT
3.1200 +0.07 (+2.30%)
After hours: 06:05PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close3.0100
Bid3.1000 x 2200
Ask3.1300 x 3000
Day's Range2.9400 - 3.1250
52 Week Range2.2300 - 7.3500
Avg. Volume1,036,516
Market Cap455.484M
Beta (5Y Monthly)2.31
PE Ratio (TTM)N/A
EPS (TTM)-0.6590
Earnings DateSep 06, 2022 - Sep 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.96
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AFMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Affimed N.V.
    Daily – Vickers Top Buyers & Sellers for 08/09/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Zacks

    Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates

    Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress

    AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated data at a scientific conference in the fourth quarter of 2022AFM24: Studies continue to enroll; data updates expected at scientific conferences in the second half of 2022AFM28: Following interactions with FDA, strategic decision to focus early clinical development in non-U.S. jurisdictions; clinica

  • GlobeNewswire

    Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

    HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call,